Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: Results of two Phase 2 randomised controlled trials

1. Wallenstein, G.V.
2. Kanik, K.S.
3. Wilkinson, B.
4. Cohen, S.
5. Cutolo, M.
6. Fleischmann, R.
7. Genovese, M.C.
8. Gomez Reino, J.
9. Gruben, D.
10. Kremer, J.
11. Krishnaswami, S.
12. Lee, E.B.
13. Pascual-Ramos, V.
14. Strand, V.
15. Zwillich, S.H.